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avb6 integrin expression in diseased and transplanted kidneys.
Background. Integrins have been implicated in the patho-
genesis of a diverse range of kidney diseases. Herein, we
provide the first detailed description of an epithelial restricted
integrin, a vb 6, in kidney biopsies from patients suffering acute
and chronic renal diseases and after transplantation.
Methods. Immunoperoxidase staining for b 6 was performed
on 267 selected biopsy specimens from native (N = 126)
and transplanted kidneys (N = 141) and scored semiquanti-
tatively. The site of b 6 expression in tubules was determined
using haematoxylin counterstaining and by colocalization with
Tamm-Horsfall protein. Comparisons were made between sub-
categories of diseases of native kidneys and between “service”
and “protocol” biopsies of transplanted kidneys.
Results. b 6, when present, is largely confined to the distal
tubules and collecting ducts, colocated with Tamm-Horsfall pro-
tein. When sparsely present, it was often restricted to the tubu-
lar segment associated with the juxtaglomerular apparatus. It
was found in tubular cells shed into the urine. b 6 was not ex-
pressed in thin membrane nephropathy, or in nonproliferative
forms of glomerulonephritis, with the exception of focal and seg-
mental glomerulosclerosis (FSGS). It was diffusely expressed
where there was glomerular necrosis or thrombosis and in most
forms of acute or chronic tubulointerstitial disease. b 6 was dif-
fusely up-regulated in allografts biopsied for delayed function,
in almost all kidneys that have clinical or subclinical rejection
episodes and was prominent in chronic allograft nephropathy.
Conclusion. b 6 integrin is not normally expressed in adult
native or transplanted kidneys but is commonly up-regulated
in the distal tubule in disease. Our descriptive study suggests
that it is a molecule worthy of further study.
Tissue repair processes are regulated, at least in part, by
cell adhesion receptors and of all the families of cell adhe-
sion molecules, the integrin family has been best charac-
terized. Individual integrins comprise an a and b subunit
in noncovalent association and there are now known to
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be 18 a subunits and 8 b subunits that can form at least 24
different heterodimers. These transmembrane receptors
provide a structural and functional bridge between the
extracellular matrix (ECM) and the intracellular cy-
toskeleton [1]. Cellular functions of integrins include
induction of cell polarity and regulation of cell migra-
tion, proliferation, differentiation, and programmed cell
death.
Multiple members of the av and b 1 integrin sub-
families have been implicated in various kidney dis-
eases. For example, in IgA nephropathy b 1 integrins
have been found to be localized to the mesangial cell
membranes in close proximity to immune complex de-
posits [2]. a2, a3, and b 1 integrins have been identi-
fied on damaged tubules raising the possibility that al-
tered b 1 integrin expression may play a role in tubu-
lointerstitial scarring in this disease [3]. In acute re-
nal failure as a consequence of ischemic injury it has
been proposed that reorganization of b 1 integrins from
basal to apical surfaces in injured tubular epithelium may
facilitate epithelial detachment contributing to tubule
obstruction and back flow of glomerular filtrate [4].
Moreover, a3b 1 at the podocyte basal plasma membrane
is thought to play a role in the dysfunction of the glomeru-
lar wall characteristic of diabetic glomerulosclerosis [5].
Expression of av integrins in proximal and distal tubu-
lar epithelium has also been observed in glomerulo
nephritis linked to the presence of macrophages within
the interstitium and the presence of markers of dis-
ease progression (interstitial fibrosis and tubular atro-
phy) [6, 7]. The majority of kidney biopsies from patients
with proteinuric glomerulonephritides, including mem-
branous and focal sclerosing glomerulonephritis, have
been shown to have up-regulated b 5 expression in tubular
cells while the integrin is not expressed in nonproteinuric
kidneys [8]. Among the av integrin subfamily a candi-
date integrin likely to play a major role in inflammatory
diseases of the kidney is avb 6. This epithelial-restricted
integrin has been shown to bind fibronectin, tenascin, and
vitronectin in a range of cell types [9–11]. avb 6 is either
not expressed or expressed at very low levels in normal
epithelia; however, it becomes highly expressed during
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inflammation, wound healing, morphogenesis, and tu-
morigenesis [12, 13].
Breuss et al [12, 14] were the first to report avb 6 in-
tegrin expression in the renal tubular epithelium of de-
veloping embryos, in diseased kidneys, and in rejected
allografts. These investigators observed b 6 expression
in distal tubules and collecting ducts in immunostained
cryostat sections of native kidney tissue obtained from
three patients suffering from hemolytic-uremic syndrome
(HUS), arterial nephrosclerosis with tubular atrophy,
and acute tubular necrosis, respectively [12]. In addi-
tion Breuss et al also analyzed cryostat sections pre-
pared from rejected, nephrectomized renal transplants
and in all cases up-regulation of b 6 expression was ob-
served in distal tubules and ducts. Our longstanding in-
terest in factors regulating b 6 expression prompted us to
use an immunohistochemical staining technique applica-
ble to preserved paraffin-embedded specimens. Herein,
we provide the first detailed analysis of b 6 expression in
biopsies from patients selected to have a comprehensive
spectrum of native kidney diseases in various stages of
evolution and also from patients with diverse problems
related to renal transplantation.
METHODS
Tissues
Native kidney diseases. Human renal biopsy material
taken for diagnostic purposes was selected retrospec-
tively from stored specimens in our hospital’s pathol-
ogy service. Cases were selected to reflect a wide variety
of native renal diseases with the histologic diagnosis hav-
ing been established by conventional light microscopy,
immunofluorescent staining, and electron microscopy.
Of the 126 biopsies studied, seven were from patients
with biopsies which were normal to light microscopy and
the remainder were from various categories of kidney
disease, namely glomerulonephritis (59 patients), tubu-
lointerstitial disease (36), and miscellaneous conditions
(thrombotic microangiopathy [10], diabetic glomeru-
losclerosis [12], and myeloma kidney [2]).
Renal transplants. In the last 5 years all our cadaveric
and live donor transplant kidneys have undergone so-
called “protocol” biopsies at time zero (on the operating
table, postreperfusion) and at 3 months posttransplant.
As part of an ongoing study these are stained for b 6 in-
tegrin expression, which is correlated with clinical, lab-
oratory, and histologic outcomes. Biopsy findings in the
first 50 such cases are presented here. As well, selected
biopsies dating from as far back as 1992 were successfully
stained to provide insight into the expression pattern of
b 6 in various diagnostic categories of allograft dysfunc-
tion [i.e., delayed graft function without acute rejection
(DGF) (nine patients), delayed graft function with acute
rejection episode (DGF + ARE) (three patients), clin-
ical acute rejection episodes (ARE) (10 patients), and
chronic allograft nephropathy (CAN) (18 patients)].
Immunoperoxidase staining
All tissues were fixed in mercuric formalin, postfixed
in Dubosq-Brazil fixative and processed to paraffin wax
(graded alcohols, histolene, wax). Sections were cut at 3 l,
placed on silanized slides and oven dried at 60◦C for
2 hours. Slides were deparaffinized and rehydrated fol-
lowed by an iodine bath and aqueous sodium thiosulphate
(hypo) solution to rid the sections of any mercury de-
posits. Antigen retrieval was performed by placing slides
in 0.1% trypsin at 37◦C for 20 minutes followed by wash-
ing with water before exposure of the sections to 3% hy-
drogen peroxide for 10 minutes to quench endogenous
peroxidase. After washing with water again the slides
were placed in Tris-buffered saline (TBS) for 10 minutes.
An avidin-biotin blocking system (Dako, Botany, NSW,
Australia) was used (10 minutes 1% avidin and 10 minutes
0.1% biotin with 10-minute TBS wash steps between) be-
fore applying normal goat serum (Newcastle Antisera,
Newcastle, Australia) diluted 1:20 for 10 minutes. The
normal goat serum was decanted before applying either
the primary antibody of interest (mouse anti-integrin b 6
monoclonal antibody diluted 1:150 (Chemicon Interna-
tional, Temecula, CA, USA) or isotype-matched control
mouse IgG1 (Auspep, Parkville, Australia) (used at a di-
lution of 1:150). The slides were incubated overnight in
a moist chamber at 4◦C and allowed to reach room tem-
perature the following day before further washing in a
TBS bath for 10 minutes. The secondary antibody, goat
antimouse (Dako) (diluted 1:500) was then applied to the
tissue sections for 30 minutes at room temperature. The
slides were again washed in TBS for 10 minutes before ap-
plication of peroxidase-labeled streptavidin (Dako) (di-
luted 1:800) for 30 minutes at room temperature followed
by another 10-minute wash in TBS.
The chromogen diaminobenzidine (DAB) was pre-
pared as per instructions (Dako) during the final
10-minute wash, applied to the slides, and the optimum
staining time (usually 5 to 10 minutes) determined by mi-
croscopic examination. The stained slides were washed in
water for 5 minutes and counterstained in Mayer’s hema-
toxylin. The final preparation of the slides consisted of a
series of graded alcohol dehydration steps and mounting
with a coverslip using Ultramount Mountant (Fronine,
Riverstone, NSW, Australia).
Staining for the presence of Tamm-Horsfall protein
was performed using sheep antihuman Tamm-Horsfall
polyclonal antibody (Chemicon) at a dilution of 1:40,000
followed by staining with secondary donkey antisheep
antibody (Amersham, Amersham, UK) at a dilution of
1:500.
Staining using both b 6 integrin and Tamm-Horsfall anti
sera was done by first staining for Tamm-Horsfall with
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Table 1. Scoring system for b 6staining
Score Description % Tubules staining for b 6
Trace Trace 0–5
1+ Focal 5–10
2+ Mild diffuse 10–20
3+ Moderate diffuse 20–30
4+ Very diffuse 30–40
A score of 4+ (30% to 40% of tubular cross-sections) means that virtually all
distal tubules and collecting ducts (i.e., all nephrons) within the kidney expressed
b 6.
DAB chromogen, and then staining for b 6 on a consecu-
tive section.
The slides were assessed by means of light microscopy
and photographed using a Nikon Coolpix 950 digital
camera. The sections were scored for b 6 expression by
two experienced renal histopathologists using a semi-
quantitative scoring system that is shown in Table 1.
Data analysis
This being a descriptive study b 6 scores were tabu-
lated by disease categories to facilitate comparisons. The
frequency distribution of b 6 scores was also represented
graphically in dot-plots using mid-points of the b 6 score
ranges to aid comparisons with linearity of scale. Post hoc
statistical analysis of the categorical data was performed
between some relevant disease categories using 2 × 2 con-
tingency tables analyzed by two-tailed Fisher’s exact test.
P values obtained were used to highlight differences be-
tween two individual categories rather than to infer any
clinical meaning to the data.
RESULTS
Patterns of b6 integrin subunit expression in
renal parenchyma
No b 6 staining was seen in biopsies that were normal
to light microscopy yet had electron microscopic fea-
tures to support a diagnosis of thin membrane nephropa-
thy (Fig. 1A). In selected biopsies of diseased kidneys
b 6 staining was largely confined to tubular epithelium
beyond the ascending loop of Henle (distal convoluted
and straight tubules and cortical and medullary collecting
ducts). Staining for b 6 in glomeruli and proximal tubules
was rarely observed except for occasional patchy staining
of the epithelium lining Bowman’s capsule in less than
5% of biopsies. There was often a predilection for the
juxtaglomerular portion of the distal tubule, including
the juxtaglomerular apparatus and adjacent tubular seg-
ment and/or cortical collecting duct (Fig. 1B and C). This
area was commonly positive in a variety of disease states
even when there was little or no staining elsewhere sug-
gesting that it is one of the first areas affected. In some
tubular segments the distribution of b 6 appeared to be
polarized to basal and lateral cell membranes (Fig. 1D)
but in most tubules b 6 staining was seen more diffusely
throughout the cell as exemplified in the biopsy of a pa-
tient with acute necrotizing glomerulonephritis, (Fig. 1E).
There were many examples of biopsies, particularly in al-
lografts with delayed function, in which all the distal tubu-
lar cross-sectional elements in the section were positive
for b 6 staining (Fig. 1F).
Strong colocalization of expression of b 6 and Tamm-
Horsfall protein (a marker for distal tubular epithelia)
was observed within tubular cross-sections suggesting
that b 6 staining was largely confined to the distal nephron
(Fig. 1G and H). Intraluminal protein casts were positive
for Tamm-Horsfall protein but not for b 6 (Fig. 1G and
H). Intraluminal casts in biopsies of patients with acute
tubulitis occasionally could be seen to contain cells stain-
ing for b 6 and b 6-stained cuboidal cells, double stained
for Tamm-Horsfall protein, were observed in the urine of
such patients (Fig. 1I).
In native kidneys with acute renal failure due to tubu-
lar necrosis b 6 staining of tubules was diffuse (median
score 3+), often despite minimal structural damage ob-
vious on light microscopy (Fig. 1J). This was also the
case with renal allografts showing delayed graft function
with or without rejection (Fig. 1K and L). In acute re-
nal failure due to severe crescentic glomerulonephritis
accompanying interstitial inflammation was associated
with very diffuse b 6 staining in tubules (Fig. 1M and
N). In severe tubulitis accompanying acute interstitial
nephritis or acute severe allograft rejection (Fig. 1O),
the inflamed tubules usually expressed b 6. On the other
hand, diffuse b 6 expression was also seen when there
was obvious chronic structural damage and minimal in-
flammation in end-stage renal failure kidneys. In these
cases b 6 was commonly seen in areas of tubular atrophy
with interstitial fibrosis (Fig. 1P), and was invariably
seen in so-called areas of “thyroidization” where dis-
tal tubules were obstructed by protein casts (Fig. 1Q).
Myeloma casts were also associated with widespread b 6
expression (Fig. 1R).
Expression of the b6 integrin subunit in native kidneys
Expression of the epithelial-restricted b 6 integrin sub-
unit was not observed in the tubular epithelium from
all seven patients with thin membrane nephropathy
confirmed on electron microscopy. In contrast, varying
degrees of heterogeneous b 6 staining were defined by im-
munohistochemistry in paraffin-embedded biopsies ob-
tained from patients suffering from glomerulonephritis
(Table 2) (Fig. 2) or miscellaneous kidney diseases
(Table 3) (Fig. 3).
Glomerulonephritis. b 6 staining was generally not
seen in nonproliferative forms of glomerulonephritis (Ta-
ble 2)(Fig. 2), with the exception of primary focal and
segmental glomerulosclerosis (FSGS) in which mild to
moderate focal tubular b 6 staining was seen in 7/7 cases.
In biopsies with acute diffuse endothelial or mesan-
gial proliferative glomerulonephritis (postinfectious, IgA
nephropathy)b 6 staining was sparse and focal with over
1426 Trevillian and Paul et al: b 6 integrin expression in native and transplanted kidneys
Fig. 1. Typical patterns of immunoperoxidase staining of b6 integrin in the renal tubular epithelium of native and transplanted kidney biopsies.
Photo micrographs of paraffin-embedded sections, prepared and stained for b 6 integrin by the immunoperoxidase technique as described in the
text and counterstained with hematoxylin. (A) No b 6 expression in the biopsy of a patient with thin membrane nephropathy. (B) Isolated staining of
cortical collecting duct in region of juxtaglomerular apparatus (arrow) in 3-month protocol biopsy of renal transplant. (C) Staining of juxtaglomeru-
lar apparatus region (arrow) and spread along adjacent tubule in renal transplant with acute interstitial rejection. (D) High power view of single
tubule with basal and lateral membrane expression of b 6 (arrow) from allograft with delayed graft function. (E) Denser staining throughout the cell
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90% of biopsies staining less than 5% of the tubular cross-
sections (0 to trace). In contrast, in the more destruc-
tive and progressive disease, acute membranoprolifera-
tive glomerulonephritis, b 6 staining was present in 100%
of biopsies and in 3/7 of these there was diffuse distal
tubular staining (score 2 to 3+). Diffuse staining was seen
in all cases of focal necrotizing glomerulonephritis with
12/13 having greater than 10% of tubules staining (2 to
4+) compared to 3/20 for the nonnecrotizing proliferative
glomerulonephritis cases (P < 0.001, Fisher’s exact test).
Biopsies showing advanced chronic glomerulonephritis
(featuring glomerulosclerosis, arteriosclerosis, tubular at-
rophy, and interstitial fibrosis) whether associated with
mesangial IgA deposits or not were also invariably dif-
fusely positive for b 6 (2 to 3+).
Miscellaneous kidney diseases: Tubulointerstitial,
metabolic, and thrombotic. Trace to very diffuse stain-
ing (trace to 4+) was seen in 14/15 patients with acute
(usually drug-induced) interstitial nephritis. For seven
patients with acute tubular necrosis all cases exhibited
very diffuse b 6 staining (3 to 4+). The biopsy from
one patient with ureteric obstruction from retroperi-
toneal fibrosis was normal to light microscopy but was
moderately diffuse (2+) for b 6. In patients suffering from
chronic renal failure secondary to chronic interstitial
nephritis, b 6 expression was absent in 23% and trace to
mildly diffuse (trace to 2+) in the remainder. b 6 staining
in this group was less marked than the afore-mentioned
chronic glomerulonephritis group (3/13 exhibiting >10%
tubular staining compared with 7/7 (P = 0.002, Fisher’s
exact test). In diabetic nephropathy, b 6 staining varied
from trace to moderately diffuse (trace to 3+) in 75% of
kidneys biopsied. Some of the most diffuse b 6 expression
(2 to 4+) was observed in thrombotic microangiopathy
(HUS/TTP) involving the majority of nephrons in 10/10
patients studied. Similarly, very diffuse staining for b 6
(4+) was seen in 2/2 patients with acute renal failure due
to myeloma kidney (Table 3) (Fig. 3).
Expression of the b6 integrin subunit in renal transplants
The data for time zero and 3-month “protocol” biopsies
from 50 sequential transplant recipients are presented
of distal tubule (arrow) in a patient with acute necrotizing glomerulonephritis. (F) Widespread staining of distal tubules (arrow) with sparing of
proximal tubules in allograft with delayed graft function. (G) Group of distal tubules stained for b 6 [note sparing of intraluminal cast (arrow)]. (H)
Same group of tubules from adjacent section showing concordant staining of tubules and casts (arrow) for Tamm-Horsfall protein, a marker for
distal tubules and collecting ducts. (I) Dual staining for b 6 (brown) and Tamm-Horsfall protein (red) of cells (arrow) in the urinary sediment of a
patient with acute interstitial nephritis [magnification (A) ×100; (B, C, F, G, and H) ×250; (D, E, and I) ×400, plus up to ×3 camera optical zoom].
(J) Low power view of very diffuse (4+) b 6 staining of distal tubules in native kidney with acute tubular necrosis. (K) Similar staining in day 5
biopsy of renal transplant with delayed graft function. (L) Similar very diffuse staining of tubules cut longitudinally from renal transplant suffering
delayed graft function and acute rejection. (M) Low power view of patient with crescentic glomerulonephritis. (N) High power view of framed area
in previous section showing only distal tubular staining for b 6 with sparing of glomerular epithelium and crescent. (O) Distal tubulitis in a patient
with acute interstitial rejection showing heavy b 6 staining of the invaded epithelium (arrow). (P) Virtually all remaining tubules (arrow) stain for
b 6 in a patient with severe end-stage chronic allograft nephropathy. (Q) b 6 staining of flattened epithelium (arrow) of dilated tubule containing
hyaline cast (“thyroidization”) in patient with chronic interstitial nephritis. (R) b 6 staining of tubules containing fractured casts (arrow) in patient
with multiple myeloma [magnification (J and M) ×100; (K, L, N, P, Q, and R) ×250; (O) ×400, plus up to ×3 camera optical zoom].
in Table 4 and Figure 4. Selected “service” biopsies per-
formed for allograft dysfunction in 40 transplant recipi-
ents are presented in Table 5 and Figure 5.
Biopsies performed routinely: “Protocol” biopsies
On table, postreperfusion biopsies (time zero). De-
spite the traumatic circumstances surrounding the death
of many kidney donors, the vast majority (98%) of time
zero renal biopsies revealed no up-regulation of b 6 in
their tubules as indicated in Table 4 and Figure 4. The
one case of 3+ staining had no particular distinguishing
histological or clinical features.
Three-month “protocol” biopsies. At 3 months post-
transplant, 33/50 (66%) of biopsies revealed some b 6
staining. Fourteen biopsies (28%) demonstrated subclin-
ical acute rejection (SAR) with the following Banff ’97
scores: suspicious, 10; 1a, 3; and 1b, 1. Eleven of 14 (79%)
of these showed b 6 positivity to varying degrees (trace to
2+). Twenty-six biopsies (52%) showed evidence of CAN
with Banff scores: 1a, 9; 1b, 15; and 2b, 2. Of these, 21/26
(81%) showed b 6 positivity (trace to 4+). In seven cases
CAN and SAR coexisted with only one such biopsy be-
ing b 6 negative. However, b 6 positivity (trace to 2+) was
also observed in 8/17 biopsies (47%) with minor trans-
plant changes only.
Biopsies performed for graft dysfunction: “Service”
biopsies
All 40 biopsies were positive for b 6 to varying degrees
as listed in the following subcategories.
DGF. Nine biopsies were from recipients whose grafts
failed to function postoperatively and were found to have
acute tubular necrosis, predominantly as a result of pro-
longed cold ischemia, and not complicated by acute re-
jection. As shown in Table 5 and Figure 5, b 6 staining was
moderate to very diffuse in 8/9 cases (3 to 4+) and mildly
diffuse (2+) in the remaining patient. The earliest biopsy
was performed on day 2 and already showed very diffuse
staining for b 6.
DGF + ARE. In a further three cases of initial non-
function there was acute interstitial rejection as well as
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Fig. 1. continued
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Table 2. b 6 integrin expression in glomerulonephritis
Number of biopsies
in each b 6 score rangeRenal disease % with b 6
category Histologic diagnosis No. staining 0 Trace 1+ 2+ 3+ 4+
“Normal” Thin membrane nephropathy 7 0 7
Non proliferative Minimal lesion nephrotic syndrome; 7 0 7 — — — — —
glomerulonephritis membranous nephropathy; 5 0 5 — — — — —
primary focal segmental glomerulosclerosis 7 100 — 2 2 2 1 —
Acute Diffuse Endocapillary glomerulonephritis; 3 67 1 1 1 — — —
proliferative mesangial IgA disease; 10 70 3 7 — — — —
glomerulonephritis membranoproliferative glomerulonephritis 7 100 — 2 2 2 1
Focal Henoch-Schonlein vasculitis; 2 100 — — — — 2 —
necrotizing pauci-immune vasculitis; 8 100 — — 1 1 3 3
glomerulonephritis anti glomerular basement membrane disease 3 100 — — — — — 3
Chronic Chronic mesangial IgA disease; 4 100 — — — 2 2 —
glomerulonephritis end-stage glomerulonephritis (unknown) 3 100 — — — 1 2 —
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Fig. 2. Distribution of averaged b6 scores as assessed by immuno-
histochemistry in paraffin-imbedded biopsies obtained from patients
suffering from glomerulonephritis. Denotes statistically significant dif-
ference in the proportion of biopsies with greater than 10% tubular
staining for b6 between acute proliferative versus focal necrotizing
glomerulonephritis (P < 0.001; Fisher exact test).
acute tubular necrosis on biopsy and these were all dif-
fusely positive (3 to 4+) for b 6.
AREs. In 11 recipients considered to have clinical re-
versible AREs (Banff scores 1a to 2b), all biopsies were
positive for b 6 (1 to 4+).
CAN. All 18 recipients in this group were biopsied
because of chronic deterioration in graft function. All
biopsies were positive for b 6 (trace to 4+).
DISCUSSION
We report herein the first description, in any tissue, of
an immunostaining technique for the b 6 subunit applica-
ble to formalin-fixed paraffin sections. This has allowed
us to study b 6 expression in archival biopsies of patients
chosen to reflect virtually the entire spectrum of renal dis-
eases in native kidneys and renal transplants. This study
provides indirect evidence that this integrin is likely to
be important in the genesis of tubular injury and repair.
By associating patterns of b 6 expression with known dis-
ease mechanisms we can speculate about the types of
injury that may lead to up-regulation of this cell surface
molecule and why its persistence may be a marker of dis-
ease progression.
Overall, 64% (170/267) of biopsies selected for this
study were positive for b 6 staining to a varying de-
gree. In many ways the biopsies (N = 97) that did not
express b 6 were as informative as those that did. In
biopsies from native kidneys, b 6 was not expressed by
the tubular epithelium in thin membrane nephropathy,
a surrogate for normal kidneys. Likewise, b 6 was not
expressed in nonproliferative glomerular diseases asso-
ciated with the nephrotic syndrome with the notable
exception of FSGS. It tends to be expressed focally
or not at all in nonnecrotizing proliferative glomerular
disease such as mesangial IgA disease or poststrepto-
coccal glomerulonephritis (although it is clearly more
prominent in membranoproliferative glomerulonephri-
tis). However, it is seen in all cases of focal necrotiz-
ing glomerulonephritis with significantly more diffuse
staining than in the nonnecrotizing group. The differ-
ence may be that in the necrotizing group there is com-
monly an interstitial component to the inflammatory
response and tubular ischemia secondary to occlusion
of glomerular capillary tufts. In this regard it is instruc-
tive that very high levels of b 6 expression are seen, by
both Breuss and us, in primary HUS where glomerular
thrombosis severely impairs tubular hemoperfusion but
without an obvious interstitial inflammatory infiltrate.
In diseases characterized by acute or chronic tubu-
lointerstitial injury/inflammation strong up-regulation
of b 6 is observed. Acute tubular necrosis induced by
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Table 3. b 6 integrin expression in miscellaneous causes of kidney failure
Number of biopsies
in each b 6 score rangeRenal disease % with b 6
category Histologic diagnosis No. staining 0 Trace 1+ 2+ 3+ 4+
Acute renal failure Acute interstitial nephritis; 15 93 1 2 3 3 4 2
acute tubular necrosis; 7 100 — — — 2 2 3
obstructive uropathy 1 100 — — — 1 — —
Chronic renal failure Chronic interstitial nephritis 13 77 3 4 3 3 — —
Metabolic Diabetic nephropathy; 12 75 3 3 3 1 2 -
myeloma kidney 2 100 — — — — — 2
Thrombotic HUS/TTP 10 100 — — — 2 4 4
0
5
10
15
20
25
30
35
40
45
%
 T
u
bu
le
s 
po
sit
ive
 fo
r b
et
a-
6
= β6+
= β6−
Ac
ut
e
in
te
rs
tit
ia
l
n
e
ph
rit
is
Ch
ro
ni
c
in
te
rs
tit
ia
l
n
e
ph
rit
is
Ac
ut
e 
tu
bu
la
r
n
e
cr
o
si
s
O
bs
tru
ct
ive
u
ro
pa
th
y
D
ia
be
tic
n
e
ph
ro
pa
th
y
M
ye
lo
m
a
ki
dn
ey
H
US
/T
TP
Fig. 3. Distribution of averaged b6 scores as assessed by immunohis-
tochemistry in paraffin-imbedded biopsies obtained from patients suf-
fering from miscellaneous causes of renal failure.
hypoperfusion of native kidneys is associated with dif-
fuse b 6 expression. It is also invariably expressed when
the tubulointerstitium is the primary inflammatory target
such as in acute interstitial nephritis of varying etiologies
(toxic, septic, and immune-mediated). The very promi-
nent b 6 staining in the two cases of multiple myeloma
suggests that this integrin may also be up-regulated in re-
sponse to intraluminal irritants. In one patient with pelvi-
calyceal dilatation from incomplete ureteric obstruction
due to retroperitoneal fibrosis the expression of mod-
erate amounts of b 6 may indicate a response to pyelo-
tubular backpressure. In chronic renal diseases such as
chronic glomerulonephritis, diabetic glomerulosclerosis,
and analgesic nephropathy, the surviving tubules in ar-
eas of tubular atrophy and replacement fibrosis usu-
ally express b 6, often very diffusely. However, chronic
glomerular disease was associated with significantly more
b 6 expression than chronic interstitial nephritis. This
finding may support the hypothesis generated from the
HUS biopsies that obliterative glomerular disease reduc-
ing tubular hemoperfusion is a potent trigger to b 6 up-
regulation in distal tubules.
In the present study we also examined a series of “ser-
vice” and “protocol” biopsies from renal transplant re-
cipients. Index biopsies were chosen from patients with
DGF (with or without acute rejection), AREs, and from
patients suffering from chronic graft deterioration. Our
findings from the “on the table” protocol biopsies indi-
cate that the b 6 integrin subunit is not usually found in
adult kidneys harvested for renal transplantation (1/50).
This almost complete negative finding was unexpected
given the cytokine release known to accompany brain
death and the likelihood that some donors would have
suffered periods of renal hypoperfusion. However, it is
further evidence that normal kidneys do not express b 6
and that it takes some time for up-regulation of b 6 af-
ter ischemia/reperfusion. By 3 months b 6 is expressed
in varying degrees in two thirds of transplant protocol
biopsies. At that time point it was more commonly ex-
pressed in patients with subclinical rejection (79%) and
with early CAN (81%) than in patients with “normal”
biopsies (47%).
The selected “service” biopsies, performed for graft
dysfunction, show that b 6 was up-regulated in 100% of
cases. DGF was strongly associated with b 6 expression
with 92% having moderate to very diffuse staining (more
than 20% of tubular cross-sections). The earliest biopsy
in this group was on day 2 posttransplant and already had
3+ staining despite a negative time zero biopsy. It is not
yet known if b 6 expression occurs in cadaveric kidneys
that function immediately as early protocol biopsies were
not performed in these patients. Grafts with good primary
function who subsequently reject also show diffuse b 6 but
possibly of a lesser grade than the DGF kidneys. All the
grafts in the CAN group were biopsied for severe and pro-
gressive graft dysfunction and all showed b 6 staining with
61% being diffuse. In many of these biopsies, the pres-
ence of quite marked tubular atrophy meant that often
most of the remaining tubular cross-sections consisted of
dilated distal tubules expressing b 6.
The rapidity with which this integrin is up-regulated
in allografts that fail to function suggests that is-
chemia/reperfusion is a major stimulus to its expres-
sion by tubular epithelium. It is known that integrins
are involved in the inflammatory response to ischemia/
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Table 4. b 6 integrin expression in protocol biopsies
Number of biopsies
in each b 6 score rangeRenal treatment % with b 6
disease category Histologic diagnosis No. staining 0 Trace 1+ 2+ 3+ 4+
On table, T0 Mild perfusion changes 50 1(2%) 49 — — — 1 —
3-month Minor transplant changes; 17 8(44%) 10 3 3 1 — —
protocol subclinical acute rejection (SAR)a 14 11(79%) 3 3 5 3 — —
biopsies chronic allograft nephropathy (CAN)a 26 21(81%) 5 8 9 3 — 1b
aSeven patients had CAN and SAR and are represented in both groups.
bGraft was obstructed by lymphocele.
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Fig. 4. Distribution of averaged b6 scores as assessed by immunohisto-
chemistry in paraffin-imbedded tissue obtained from “protocol” biop-
sies in renal transplant recipients. Denotes statistically significant dif-
ference in the proportion of biopsies exhibiting any b6 tubular staining
in chronic allograft nephropathy versus minor transplant changes (P
= 0.01; Fisher exact test). N.S. denotes no statistically significant dif-
ferences in proportion of biopsies exhibiting any b6 tubular staining in
patients with SAR versus minor transplant changes (P = 0.07; Fisher
exact test).
reperfusion injury. Ischemia/reperfusion injury involves
adhesion of leukocytes to the activated endothelium lead-
ing to tissue damage. Therapeutic strategies that target
leukocytes using either monoclonal antibodies, antisense
oligonucleotides, or gene knockout blockade of b 2 in-
tegrins and intercellular adhesion molecule-1 (ICAM-1)
have been shown to attenuate acute renal failure in ex-
perimental models of renal ischemia [15]. Mononuclear
cell infiltrates are found in ischemia/reperfusion injury
and it has been suggested that adhesion of infiltrating T
cells to renal tubular cells may provide a potential mech-
anism underlying postischemia tubular dysfunction [16].
However, it remains to be determined whether the main
stimulus to b 6 is hypoxia alone or the known inflamma-
tory response that accompanies reperfusion, or both.
In acute rejection most lymphocytic tubulitis involves
the distal tubule and collecting ducts [17, 18], which is the
common site for b 6 expression, raising speculation that
b 6 may partake in the alloimmune response. b 6 expres-
sion does colocate with areas of active tubulitis although
not invariably suggesting that, in acute rejection, mecha-
nisms other than the interaction between tubule and cyto-
toxic T cell may be important in the de novo expression
of b 6. Later, the expression of b 6 in chronically failing
grafts could be secondary to (chronic) ischemia/hypoxia
brought about by thickening of basement membranes of
peritubular capillaries but could also be the consequence
of direct tubular injury from chronic inflammatory cells
or drug toxicity.
The use of counterstained paraffin-imbedded sections
enabled us to determine that b 6 staining was restricted
nearly exclusively to the distal tubules and collecting
ducts. In double staining experiments b 6 was closely colo-
cated with Tamm-Horsfall protein, a marker of distal
tubules [19]. Distal tubular cells are the site of constitu-
tive expression of a number of regulatory cytokines such
as osteopontin [20], regulated upon activation, normal T
cell expressed and secreted (RANTES) [21], and mono-
cyte chemoattractant protein-1 (MCP-1) [22] suggesting
that distal tubular epithelial elements may be more ac-
tive than proximal segments in maintaining the integrity
of the tubulointerstitium at times of injury. Following is-
chemia/reperfusion injury necrosis has been shown to
occur mainly in the proximal tubules, while the distal
nephron survives [23]. The mechanism(s) whereby distal
tubule cells remain relatively protected from ischemia ap-
pears to involve the mitogen-activated protein (MAP) ki-
nase signaling pathway. For example, in an animal model,
activation of the MAP kinases called extracellular signal-
regulated kinases (ERKs) following oxidant injury has
been observed only in the ascending limb but not proxi-
mal tubule cells [23]. We have recently reported that the
cytoplasmic domain of the b 6 integrin subunit binds di-
rectly to ERK2 [24]. Whether b 6-bound ERK2 within the
distal renal tubule cells plays a role in protection from is-
chemic injury remains to be investigated but it does raise
the possibility that b 6 up-regulation in the distal nephron
may act as a survival signal. In chronic renal disorders, the
inflammatory cytokine transforming growth factor beta
(TGF-b) is thought to play a major role in promoting
tubulo-epithelial hypertrophy and fibrosis [25]. The avb 6
integrin binds not only matrix ligands such fibronectin
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Table 5. b 6 integrin expression in service biopsies
Number of biopsies
in each b 6 score rangeRenal treatment % with b 6
disease category Histologic diagnosis No. staining 0 Trace 1+ 2+ 3+ 4+
Graft dysfunction Delayed graft function 9 9(100%) — — — 1 5 3
DGF + Acute rejection 3 3(100%) — — — — 1 2
Acute rejection 11 11(100%) — — 6 1 3 1
Chronic allograft nephropathy 18 18(100%) — 1 6 2 6 3
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Fig. 5. Distribution of averaged b6 scores as assessed by immunohisto-
chemistry in paraffin-imbedded tissue obtained from “service” biopsies
of dysfunctional renal allografts.
and tenascin but has also been shown to bind and activate
latent TGF-b in normal and malignant cells [26]. TGF-b
can itself up-regulate b 6 expression in epithelial cells [27,
28] raising the possibility that TGF-b autoregulation of
b 6 expression occurs in tubular cells of chronically hy-
poperfused kidneys.
Following renal transplantation, a strong link has been
observed between the occurrence of AREs and the even-
tual development of chronic rejection leading to graft
loss. This has lead to the search for an early marker
that will identify those grafts at risk of chronic rejec-
tion and, thereby, allow for early use of rescue strategies.
Despite an exhaustive examination of different proteins,
cytokines, and inflammatory cells in early posttransplant
biopsies, only a few markers have proved to have value
in predicting progressive graft failure in a cohort of ap-
parently stable grafts [29]. None of these is a specific
marker of ongoing damage to the tubular epithelium. In
our study it appears that de novo b 6 expression in renal
transplants results predominantly from acute tubular is-
chemia/reperfusion injury at the time of transplantation.
De novo expression may also occur from direct interac-
tion of immune effector cells with distal tubular epithe-
lium as witnessed by the ten patients with no clinically
obvious DGF preceding their acute rejection (although
early protocol biopsies would be necessary to exclude
prior expression of b 6 in these patients). Subsequently,
reversible and/or irreversible vascular changes secondary
to rejection or drug nephrotoxicity may further add to the
ischemic damage and thereby enhance b 6 expression. It
seems likely that b 6 is up-regulated each time the allograft
suffers one of these “hits” and its presence in protocol
biopsies may be a useful marker to identify patients with
a long-term unfavorable outcome following transplanta-
tion. Studies to address this are ongoing in our unit.
The reason for the negative findings in a few biopsies
expected to be positive is unclear but may relate to lack
of success in antigen retrieval and hence antibody bind-
ing. Alternatively, there may be some individuals who
fail to express b 6 when provoked. The study is retrospec-
tive and the biopsies were selected arbitrarily from dis-
ease categories without quantifying duration or severity.
Only in the case of the protocol transplant biopsies does
it reflect consecutive patient sampling of a single cohort.
Like other studies we are assuming that thin membrane
nephropathy equates with normal controls. We did not
set out to look at clinical correlations of b 6 staining or
its time course in iterative biopsies. However, this study
is the first comprehensive description of patterns of avb 6
expression in renal disease and transplantation. From it
we conclude that avb 6 integrin is likely to be a pivotal
molecule in the genesis of renal injury and repair and
warrants further study at a clinical and molecular level.
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